Cases 31 - 40 of 146
In re: Sitagliptin Phosphate ('708 & '921) Patent Litigation
as 1:2019md02902
Counter Defendant:
Merck Sharp & Dohme Corp.
Not Classified By Court:
Teva Pharmaceuticals USA, Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Limited and others
Counter Claimant:
Macleods Pharmaceuticals Limited
In Re:
In re: Sitagliptin Phosphate ('708 & '921) Patent Litigation
Defendant:
Accord Healthcare, Inc., Teva Pharmaceutical Industries Ltd., Inventia Healthcare Ltd. and others
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Keryx Biopharmaceuticals, Inc et al v. Mylan Pharmaceuticals Inc.
as 1:2019cv01445
Plaintiff:
Panion & BF Biotech, Inc., Keryx Biopharmaceuticals, Inc. and Chen Hsing Hsu
Defendant:
Mylan Pharmaceuticals Inc.
Cause Of Action: 35 U.S.C. § 271
In re: Auryxia (Ferric Citrate) Patent Litigation
as 1:2019md02896
Not Classified By Court:
Chemo Research S.L., Insud Pharma S.L., Teva Pharmaceuticals USA, Inc. and others
Counter Defendant:
Keryx Biopharmaceuticals, Inc., Panion & BF Biotech, Inc. and Chen Hsing Hsu
Counter Claimant:
Lupin Atlantis Holdings SA and Lupin Ltd.
In Re:
In re: Auryxia (Ferric Citrate) Patent Litigation
Cause Of Action: 35 U.S.C. § 271
Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals, Inc.
as 1:2019cv01118
Defendant:
Mylan Pharmaceuticals, Inc.
Plaintiff:
Novartis Pharmaceuticals Corporation
Cause Of Action: 28 U.S.C. § 2201
Novartis Pharmaceuticals Corporation et al v. Mylan Pharmaceuticals Inc.
as 1:2019cv01042
Defendant:
Mylan Pharmaceuticals Inc.
Plaintiff:
Novartis Pharmaceuticals Corporation and Novartis AG
Cause Of Action: 35 U.S.C. § 271
Pfizer Inc. et al v. Mylan Pharmaceuticals Inc. et al
as 1:2019cv00752
Plaintiff:
Pfizer Manufacturing Holdings LLC, Pfizer PFE Ireland Pharmaceuticals Holding 1 B.V., Pfizer Inc. and others
Defendant:
Mylan Pharmaceuticals Inc. and Mylan Inc.
Cause Of Action: 35 U.S.C. § 271
Anacor Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. et al
as 1:2019cv00632
Defendant:
Mylan Pharmaceuticals Inc. and Mylan Inc.
Plaintiff:
Anacor Pharmaceuticals, Inc.
Cause Of Action: 35 U.S.C. § 271
In re: Kerydin (Tavaborole) Topical Solution 5% Patent Litigation
as 1:2019md02884
Counter Claimant:
Glasshouse Pharmaceuticals Limited Canada
Not Classified By Court:
Taro Pharmaceuticals U.S.A., Inc., Aurobindo Pharma Limited, Zydus Pharmaceuticals (USA) Inc. and others
In Re:
Kerydin (Tavaborole) Topical Solution 5% Patent Litigation
Counter Defendant:
Anacor Pharmaceuticals, Inc.
Cause Of Action: 35 U.S.C. § 271
Merck Sharp & Dohme Corp. v. Mylan Pharmaceuticals Inc., et al.
as 1:2019cv00315
Defendant:
Mylan Pharmaceuticals Inc. and Mylan Inc.
Plaintiff:
Merck Sharp & Dohme Corp.
Cause Of Action: 35 U.S.C. § 271
Anacor Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. et al
as 1:2018cv01699
Defendant:
Mylan Pharmaceuticals Inc. and Mylan Inc.
Plaintiff:
Anacor Pharmaceuticals, Inc.
Cause Of Action: 35 U.S.C. § 271
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
